Abstract 201P
Background
Immunotherapy provided a new treatment alternative for cancer, but many patients still do not respond due to tumor-induced immunological dysfunction. Aerobic exercise training (AET) has emerged as a strategy to reduce cancer mortality and improve immune response, however the mechanisms explaining AET benefits immune system on cancer remain unclear. Thus, our aim was to evaluate whether AET could positively modify the tumor microenvironment, favoring infiltration and cytotoxicity of “antitumor” lymphocytes by regulating their mitochondrial content and function.
Methods
Balb/c male mice were submitted to 4 weeks of AET (60% of maximal capacity, 5 days/week, 1 h/day) before inoculation (s.c.,1x106 CT26 colon carcinoma cells). CT26 TR continued AET after inoculation and all groups were euthanized 9 days post tumor cells inoculation for further analysis. Tumor volume was measured daily. Experimental groups were divided into control (healthy sedentary mice), CT26 SED (sedentary tumor-bearing mice) and CT26 TR (trained tumor-bearing mice). Tumor-infiltrated T lymphocytes and mitochondrial density were measured by flow cytometry. Tumor hypoxia was measured by Hypoxyprobe Kit. Mitochondrial morphology was evaluated by electron microscopy and ATP production by an ATP Determination Kit. Statistical analysis: Anova One-way, Duncan post hoc, p<0.05. Ethical approval: CEUA EEFE-USP 2017/02.
Results
CT26 TR mice showed attenuated tumor progression when compared with CT26 SED group, with significant smaller tumor volume and mass. AET significantly reduced tumor hypoxic area compared to CT26 SED group. AET significantly increased the total amount of activated and effector memory CD8+ T cells, and effector memory CD4+ T cells in CT26 TR when compared to CT26 SED in the tumor. Additionally, increased function of T CD8+ cells in CT26 TR was followed by a higher mitochondrial number/cell and function (ATP production) in this cells compared with CT26 SED group.
Conclusions
AET increases tumor-infiltrated cytotoxic/effector CD8+ T cells and improves their mitochondrial content and function. These data suggest that AET can attenuate tumor growth by modulation of tumor-infiltrated lymphocytes number and profile.
Legal entity responsible for the study
The authors.
Funding
São Paulo Research Foundation (FAPESP, 11800-4/2021, 2015/22814-5, and 2017/13133-0).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
156TiP - The LUNGVAC-study; A randomized phase II, open-label, multicenter study investigating efficacy and safety of anti-PD-1/PD-L1 treatment +/- UV1 vaccination as first line treatment in patients with inoperable advanced or metastatic non-small cell lung cancer (NSCLC)
Presenter: Elin Marie Stensland
Session: Poster Display
157TiP - Krascendo-170 Lung: a phase Ib/II study of divarasib + pembrolizumab _ platinum-based chemotherapy and pemetrexed in untreated KRAS G12C+ advanced non-small cell lung cancer (NSCLC)
Presenter: Ferdinandos Skoulidis
Session: Poster Display
159TiP - Two Phase 1 Studies Assessing the Safety and Efficacy of the Small Molecule Oral PD-L1 Inhibitor INCB099280 in Combination with Adagrasib (INCB 99280-204 [Study 204]) or Ipilimumab (INCB 99280-205 [Study 205]) in Adults with Advanced Solid Tumors
Presenter: David Berz
Session: Poster Display
160TiP - Safety and Antitumor Activity of GEN1042 in Combination with Pembrolizumab _ Chemotherapy in Solid Tumors: Phase 2b Dose-Expansion Trial in Progress
Presenter: Ignacio Melero
Session: Poster Display
164P - Disentangling the Joint and Distinct Immunomodulation and Vulnerability Between KEAP1/NFE2L2 and SMARCA4 Alterations in Lung Adenocarcinoma
Presenter: Anlin Li
Session: Poster Display
165P - Immunosuppressive F13A1+ Mo/M_ in the tumor microenvironment as a hallmark for multiple primary lung cancers
Presenter: Jiahao Qu
Session: Poster Display
166P - Three-dimensional (3D) Innervation of Mouse Lungs and Airways in a Lung Metastatic Tumor Model
Presenter: Yan Zhou
Session: Poster Display
167P - Lurbinectedin, a DNA minor groove inhibitor launches a multimodal immune response through activation of the cytosolic DNA-Sensing cGAS-STING pathway.
Presenter: Triparna Sen
Session: Poster Display
168P - Effect of sequence treatment of chemotherapy plus radiotherapy activates innate immunity in SCLC
Presenter: CATERINA DE ROSA
Session: Poster Display